ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Meng, Erhong ^a   Mitra, Aparna ^a   Tripathi, Kaushlendra ^a   Finan, Michael A ^a   Scalici, Jennifer ^a   McClellan, Steve ^a   Da Silva, Luciana Madeira ^a   Reed, Eddie ^b   Shevde, Lalita A ^c   Palle, Komaraiah ^a   Rocconi, Rodney P ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE 1A1; BRCA1 PROTEIN; CARBOPLATIN; CHECKPOINT KINASE 1; CISPLATIN; FANCONI ANEMIA GROUP D2 PROTEIN; FANCONI ANEMIA GROUP J PROTEIN; HISTONE H2AX; KRUPPEL LIKE FACTOR 4; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NUCLEAR PROTEIN; OXIDOREDUCTASE; PHOSPHOPROTEIN; PLATINUM COMPLEX; PROTEIN BAX; PROTEIN P21; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ALDEHYDE DEHYDROGENASE; ALDH1A1 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; ISOENZYME; KRUPPEL LIKE FACTOR; PLATINUM;

APOPTOSIS; ARTICLE; ASCITES; CANCER INHIBITION; CANCER RECURRENCE; CANCER STEM CELL; CANCER SURVIVAL; CELL CYCLE CHECKPOINT; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CLINICAL ARTICLE; CLONOGENESIS; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; OVARIAN CANCER CELL LINE; OVARY CANCER; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; DISEASE FREE SURVIVAL; DOWN REGULATION; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; PHENOTYPE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ALDEHYDE DEHYDROGENASE; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE-FREE SURVIVAL; DNA REPAIR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; ISOENZYMES; KRUPPEL-LIKE TRANSCRIPTION FACTORS; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; PHENOTYPE; PLATINUM; SIGNAL TRANSDUCTION;

EID: 84909613368     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107142     Document Type: Article

References (45)

1. Eisenhauer EA, Vermorken JB, van Glabbeke M (1997) Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]. Ann Oncol Off J Eur Soc Med Oncol ESMO 8: 963-968.
2. Soltanian S, Matin MM (2011) Cancer stem cells and cancer therapy. Tumour Biol J Int Soc Oncodevelopmental Biol Med 32: 425-440.
3. Bapat SA (2010) Human ovarian cancer stem cells. Reprod Camb Engl 140: 33-41.
4. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, et al. (2009) Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res MCR 7: 330-338.
5. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, et al. (2010) Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res 16: 45-55.
6. Li T, Su Y, Mei Y, Leng Q, Leng B, et al. (2010) ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Investig J Tech Methods Pathol 90: 234-244.
7. Todaro M, Iovino F, Eterno V, Cammareri P, Gambara G, et al. (2010) Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res 70: 8874-8885.
8. Clay MR, Tabor M, Owen JH, Carey TE, Bradford CR, et al. (2010) Singlemarker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck 32: 1195-1201.
9. Ma I, Allan AL (2011) The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev 7: 292-306.
10. Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, et al. (2010) Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 9: 3186-199.
11. He Q-Z, Luo X-Z, Wang K, Zhou Q, Ao H, et al. (2014) Isolation and characterization of cancer stem cells from high-grade serous ovarian carcinomas. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 33: 173-1784.
12. Xiang T, Long H, He L, Han X, Lin K, et al. (2013) Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133(+) cancer stem-like cells in ovarian cancer. Oncogene.
13. Yokota A, Takeuchi H, Maeda N, Ohoka Y, Kato C, et al. (2009) GM-CSF and IL-4 synergistically trigger dendritic cells to acquire retinoic acid-producing capacity. Int Immunol 21: 361-377.
14. Wang Y-C, Yo Y-T, Lee H-Y, Liao Y-P, Chao T-K, et al. (2012) ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome. Am J Pathol 180: 1159-1169.
15. Liu S, Ginestier C, Charafe-Jauffret E, Foco H, Kleer CG, et al. (2008) BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A 105: 1680-1685.
16. Madjd Z, Gheytanchi E, Erfani E, Asadi-Lari M (2013) Application of stem cells in targeted therapy of breast cancer: a systematic review. Asian Pac J Cancer Prev APJCP 14: 2789-2800.
17. Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108: 171-182.
18. Bunting SF, Callén E, Wong N, Chen H-T, Polato F, et al. (2010) 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141: 243-254.
19. Kakarougkas A, Jeggo P (2014) DNA DSB repair pathway choice: an orchestrated handover mechanism. Br J Radiol 87(1035): 20130685.
20. Li QQ, Lee RX, Liang H, Wang G, Li JM, et al. (2013) b-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK. Int J Oncol 43: 721-728.
21. Meng E, Long B, Sullivan P, McClellan S, Finan MA, et al. (2012) CD44+/CD242 ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clin Exp Metastasis 29: 939-9348.
22. Mabuchi S, Hisamatsu T, Kawase C, Hayashi M, Sawada K, et al. (2011) The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary. Clin Cancer Res Off J Am Assoc Cancer Res 17: 4462-4473.
23. Cartee L, Kucera GL, Willingham MC (1998) Induction of apoptosis by gemcitabine in BG-1 human ovarian cancer cells compared with induction by staurosporine, paclitaxel and cisplatin. Apoptosis Int J Program Cell Death 3: 439-449.
24. Zhen W, Link CJ Jr, O'Connor PM, Reed E, Parker R, et al. (1992) Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 12: 3689-3698.
25. Parker RJ, Eastman A, Bostick-Bruton F, Reed E (1991) Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 87: 772-777.
26. Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, et al. (2012) Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res Off J Am Assoc Cancer Res 18: 869-881.
27. Yu F, Li J, Chen H, Fu J, Ray S, et al. (2011) Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene 30: 2161-2172.
28. Jia Y, Zhang W, Liu H, Peng L, Yang Z, et al. (2012) Inhibition of glutathione synthesis reverses Krüppel-like factor 4-mediated cisplatin resistance. Cancer Chemother Pharmacol 69: 377-385.
29. Er E, Oliver L, Cartron P-F, Juin P, Manon S, et al. (2006) Mitochondria as the target of the pro-apoptotic protein Bax. Biochim Biophys Acta 1757: 1301-11.
30. Palle K, Vaziri C (2011) Rad18 E3 ubiquitin ligase activity mediates Fanconi anemia pathway activation and cell survival following DNA Topoisomerase 1 inhibition. Cell Cycle Georget Tex 10: 1625-1638.
31. D'Andrea AD (2003) The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. Cell Cycle Georget Tex 2: 290-292.
32. Wu Y, Brosh RM Jr (2009) FANCJ helicase operates in the Fanconi Anemia DNA repair pathway and the response to replicational stress. Curr Mol Med 9: 470-4782.
33. Zhang S, Balch C, Chan MW, Lai H-C, Matei D, et al. (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68: 4311-4320.
34. Alvero AB, Chen R, Fu H-H, Montagna M, Schwartz PE, et al. (2009) Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle Georget Tex 8: 158-166.
35. Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, et al. (2009) CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells Dayt Ohio 27: 2875-2883.
36. Shi MF, Jiao J, Lu WG, Ye F, Ma D, et al. Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line. Cell Mol Life Sci CMLS 67: 3915-3925.
37. Silva IA, Bai S, McLean K, Yang K, Griffith K, et al. (2011) Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 71: 3991-4001.
38. Suman S, Das TP, Damodaran C (2013) Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells. Br J Cancer 109: 2587-2596.
39. Zhang Z, Dong Z, Lauxen IS, Filho MS, Nör JE (2014) Endothelial cell-secreted EGF induces epithelial to mesenchymal transition and endows head and neck cancer cells with stem-like phenotype. Cancer Res 74: 2869-2881.
40. Liu S, Cong Y, Wang D, Sun Y, Deng L, et al. (2014) Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts. Stem Cell Rep 2: 78-91.
41. Zhou W, Lv R, Qi W, Wu D, Xu Y, et al. (2014) Snail contributes to the maintenance of stem cell-like phenotype cells in human pancreatic cancer. PloS One 9: e87409.
42. Rowland BD, Peeper DS (2006) KLF4, p21 and context-dependent opposing forces in cancer. Nat Rev Cancer 6: 11-23.
43. Ghaleb AM, Katz JP, Kaestner KH, Du JX, Yang VW (2007) Krüppel-like factor 4 exhibits antiapoptotic activity following gamma-radiation-induced DNA damage. Oncogene 26: 2365-2373.
44. Zhou Q, Hong Y, Zhan Q, Shen Y, Liu Z (2009) Role for Kruppel-like factor 4 in determining the outcome of p53 response to DNA damage. Cancer Res 69: 8284-8292.
45. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816.